潘糖 | 33401-87-5

• 物质功能分类: 生物化工 - 糖类化合物 - 寡糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 潘糖
• 中文别名: 潘糖(异构体混合物)
• 英文名称: panose
• 英文别名: (2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal
• CAS: 33401-87-5
• 化学式: C₁₈H₃₂O₁₆
• 分子量: 504.442
• InChiKey: ZCLAHGAZPPEVDX-MQHGYYCBSA-N

物化性质

• 熔点：
  223 °C
• 沸点：
  960.0±65.0 °C(Predicted)
• 密度：
  1.75±0.1 g/cm3(Predicted)
• 溶解度：
  Soluble (water)
• LogP：
  -5.563 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  -7.2
• 重原子数：
  34
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  277
• 氢给体数：
  11
• 氢受体数：
  16

安全信息

• WGK Germany：
  3
• 海关编码：
  29400090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

用途
D- mannose 已被用于研究确定含有混合关联碳-13 核磁共振葡聚糖的组成和序列，并且也用于探讨糖异构体在电泳中的行为特性。

反应信息

• 作为反应物：
  描述：

  潘糖 在 Arthrobacter sp. DL001 α-D-glucoside glucohydrolase 、 水 作用下， 反应 0.5h， 生成 葡萄糖
  参考文献：
  名称：

  Isolation and characterization of a novel α-glucosidase with transglycosylation activity from Arthrobacter sp. DL001

  摘要：

  A strain of Arthrobacter sp. DL001 with high transglycosylation activity was successfully isolated from the Yellow Sea of China. To purify the extracellular enzyme responsible for transglycosylation, a four-step protocol was adopted and the enzyme with electrophoretical purity was obtained. The purified enzyme has a molecular mass of 210 kDa and displays a narrow hydrolysis specificity towards alpha-1,4-glucosidic bond. Its hydrolytic activity was identified as decreasing in the order of maltotriose > panose > maltose. Only 3.61% maltose activity occurs when p-nitrophenyl alpha-D-glycopyranoside serves as a substrate, suggesting that this enzyme belongs to the type II alpha-glucosidase. In addition, the enzyme was able to transfer glucosyl groups from the donors containing alpha-1,4-glucosidic bond specific to glucosides, xylosides and alkyl alcohols in alpha-1,4- or alpha-1,6-manners. A decreased order of activity was observed when maltose, maltotriose, panose, beta-cyclodextrin and soluble starch served as glycosyl donors, respectively. When maltose was utilized as a donor and a series of p-nitrophenyl-glycosides as acceptors, the glucosidase was capable of transferring glucosyl groups to p-nitrophenyl-glucosides and p-nitrophenyl-xylosides in alpha-1,4- or alpha-1,6-manners. The yields of p-nitrophenyl-oligosaccharides could reach 42-60% in 2 h. When a series of alkyl alcohols were utilized as acceptors, the enzyme exhibited its transglycosylation activities not only to the primary alcohols but also to the secondary alcohols with carbon chain length 1-4. Therefore, all the results indicated that the purified alpha-glucosidase present a useful tool for the biosynthesis of oligosaccharides and alkyl glucosides. (C) 2012 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molcatb.2012.04.016
• 作为产物：
  描述：

  D-(+)-纤维二糖 在 水 作用下， 以 乙酸盐 为溶剂， 反应 1.75h， 生成 潘糖
  参考文献：
  名称：

  Method for determination of transglucosidase

  摘要：

  本发明公开了一种用于测定怀疑具有转葡萄糖苷酶活性的葡萄糖淀粉酶制剂中转葡萄糖苷酶活性的方法。该方法涉及使用阿卡波糖抑制制剂中的葡萄糖淀粉酶，然后通过传统方法测量未被抑制的转葡萄糖苷酶活性。

  公开号：

  US04575487A1

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• [EN] POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS<br/>[FR] CONSTRUCTIONS POLYNUCLÉOTIDIQUES CONTENANT DES GROUPES DISULFURE
  申请人：SOLSTICE BIOLOG LTD

  公开号：WO2015069932A1

  公开（公告）日：2015-05-14

  The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internudeotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.

  该发明涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）包含靠近二硫键的一个或多个臃肿基团。该发明还涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分（i）连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）在二硫键和核苷酸桥连基团或末端基团的磷原子之间的链中至少包含4个原子；并且该链不包含磷酸酯、酰胺、酯或烯基烃。该发明还涉及使用该发明的聚核苷酸构造将聚核苷酸传递到细胞的方法。
• LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTALLINE COMPOSITION, ANISOTROPICALLY LIGHT-ABSORBING FILM, AND LIQUID CRYSTAL DISPLAY DEVICE
  申请人：FUJIFILM Corporation

  公开号：EP2554536A1

  公开（公告）日：2013-02-06

  Provided is a novel azo liquid-crystal compound that is capable of orientation with a high degree of orientation order The liquid-crystal compound denoted by general formula I) below:wherein each of R1 and R2 denotes a hydrogen atom, alkyl group, alkoxy group, or substituent denoted by -L2-Y, with at least one of the two denoting a group other than a hydrogen atom; L2 denotes an alkylene group in which one CH2 group, or two or more nonadjacent CH2 groups, are optionally substituted with -O-, -COO-, -OCO-, -OCOO-, -NRCOO-, -OCONR-, -CO-, -S-, -SO2-, -NR-, -NRSO2-, or - SO2NR- (where R denotes a hydrogen atom or an alkyl group with 1 to 4 carbon atoms); Y denotes a hydrogen atom, hydroxy group, alkoxy group, carboxyl group, halogen atom, or polymerizable group; each instance of L1 denotes a linking group selected from the group consisting of azo groups (-N=N-), carbonyloxy groups (-C(=O)O-), oxycarbonyl groups (-O-C(=O)-) imino groups (-N=CH-), and vinylene groups (-C=C-); and each instance of Dye denotes an azo dye residue denoted by general formula (II).

  提供了一种新型的偶氮液晶化合物，能够具有高度有序的取向。该液晶化合物由下面的一般式I)表示：其中R1和R2中的每一个代表氢原子、烷基、烷氧基或由-L2-Y表示的取代基，其中至少有一个不是氢原子；L2代表一种烷基链，其中一个CH2基团或两个或更多非相邻的CH2基团可选地被-O-、-COO-、-OCO-、-OCOO-、-NRCOO-、-OCONR-、-CO-、-S-、-SO2-、-NR-、-NRSO2-或-SO2NR-（其中R代表一个氢原子或含有1至4个碳原子的烷基）所取代；Y代表一个氢原子、羟基、烷氧基、羧基、卤素原子或可聚合基团；每个L1代表从偶氮基团（-N=N-）、羰氧基团（-C(=O)O-）、氧羰基团（-O-C(=O)-）、亚氨基团（-N=CH-）和乙烯基团（-C=C-）中选择的连接基团；每个Dye代表由一般式（II）表示的偶氮染料残基。
• MultiLigand Agent for Drug Delivery
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20170028074A1

  公开（公告）日：2017-02-02

  Described herein is a compound having the structure of formula I, II, or III, wherein R comprises a double stranded RNA molecule, and L 1 , L 2 , and L 3 independently for each occurrence comprise a ligand selected from the group consisting of a carbohydrate, a cholesteryl, or a peptide; a pharmaceutically accepted salt or pharmaceutical composition thereof; and a method of making the compound.

  本文描述了一种具有化学式I、II或III结构的化合物，其中R包括一种双链RNA分子，而每次出现的L1、L2和L3独立地包括从碳水化合物、胆固醇或肽组成的配体中选择的配体；以及该化合物的药学接受的盐或药物组合物；以及制备该化合物的方法。
• [EN] COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY<br/>[FR] COMPOSITIONS ET MÉTHODES D'ADMINISTRATION CIBLÉE D'ARN
  申请人：VERVE THERAPEUTICS INC

  公开号：WO2021178725A1

  公开（公告）日：2021-09-10

  Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease.

  本文提供了组合物、制备方法以及用于靶向传递治疗剂以修改靶基因表达和功能的方法，例如涉及脂质和胆固醇代谢的蛋白质，如PCSK9。此外，还提供了与冠心病相关疾病的治疗组合物和方法。